Literature DB >> 23062470

Drug Reaction with Eosinophilia and Systemic Symptoms: an update on pathogenesis.

Xavier Camous1, Sebastien Calbo, Damien Picard, Philippe Musette.   

Abstract

The syndrome termed 'Drug Reaction with Eosinophilia and Systemic Symptoms' (DRESS) is an unpredictable, life-threatening condition associated with adverse reactions to therapy. Although the etiology of DRESS is poorly understood, genetic susceptibility markers have been identified within the HLA complex and there are several prevailing models of pathogenesis. Modification of host antigens by haptens (drugs or their metabolites), or non-covalent drug binding to endogenous proteins (the p-i concept), may drive pro-inflammatory immune responses in patients. Alternatively, a viral trigger for DRESS has been proposed based on the concomitant detection of herpesviruses and the recent demonstration of Epstein-Barr virus-specific immune responses in DRESS patients. In the present review, we discuss the latest findings concerning the pathogenesis of drug reactions and known risk factors for DRESS.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23062470     DOI: 10.1016/j.coi.2012.07.010

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  15 in total

Review 1.  [Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): a review].

Authors:  S Ständer; D Metze; T Luger; T Schwarz
Journal:  Hautarzt       Date:  2013-08       Impact factor: 0.751

2.  Drug Reaction, Eosinophilia and Systemic Symptoms (DRESS) syndrome secondary to allopurinol with early lymphadenopathy and symptom relapse.

Authors:  Rhiannon Turney; Jordan Peter Skittrall; Joseph Donovan; Daniel Agranoff
Journal:  BMJ Case Rep       Date:  2015-10-05

3.  Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome secondary to antituberculosis drugs and associated with human herpes virus-7 (HHV-7).

Authors:  Nehal Draz; Sumona Datta; Daniel P Webster; Ian Cropley
Journal:  BMJ Case Rep       Date:  2013-07-31

Review 4.  The Role and Immunobiology of Eosinophils in the Respiratory System: a Comprehensive Review.

Authors:  Stephanie S Eng; Magee L DeFelice
Journal:  Clin Rev Allergy Immunol       Date:  2016-04       Impact factor: 8.667

5.  Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy.

Authors:  Douglas B Johnson; Erika K Wallender; Daniel N Cohen; Sunaina S Likhari; Jeffrey P Zwerner; Jennifer G Powers; Lisa Shinn; Mark C Kelley; Richard W Joseph; Jeffrey A Sosman
Journal:  Cancer Immunol Res       Date:  2013-12       Impact factor: 11.151

6.  [Systemic therapy of rosacea].

Authors:  M Schaller; K Belge
Journal:  Hautarzt       Date:  2013-07       Impact factor: 0.751

7.  Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A National Analysis of Data from 10-Year Post-marketing Surveillance.

Authors:  Francesca Renda; Giovanni Landoni; Renato Bertini Malgarini; Alessandro Assisi; Maria Luisa Azzolini; Marta Mucchetti; Giuseppe Pimpinella; Luca Pani
Journal:  Drug Saf       Date:  2015-12       Impact factor: 5.228

8.  Comparison of diagnostic criteria and determination of prognostic factors for drug reaction with eosinophilia and systemic symptoms syndrome.

Authors:  Dong-Hyun Kim; Young-Il Koh
Journal:  Allergy Asthma Immunol Res       Date:  2014-02-06       Impact factor: 5.764

9.  Pustular drug hypersensitivity syndrome due to allopurinol.

Authors:  Chaker Ben Salem; Wafa Saidi; Sofiene Larif; Neila Fathallah; Raoudha Slim; Houssem Hmouda
Journal:  Indian J Pharmacol       Date:  2015 Jan-Feb       Impact factor: 1.200

Review 10.  Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical Implementation.

Authors:  Shih-Chi Su; Shuen-Iu Hung; Wen-Lang Fan; Ro-Lan Dao; Wen-Hung Chung
Journal:  Int J Mol Sci       Date:  2016-11-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.